FGFRs x PDGFR x FLT3 x JAK x VEGFR x HPK1 - 药物、适应症、专利

A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors

This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.

开始日期2022-07-31

申办/合作机构

Maxinovel Pty., Ltd.

CTR20220826

/ Active, not recruiting临床2期

一项评估MAX-40279（多靶点酪氨酸激酶抑制剂）联合KN046（抗PD-L1/CTLA-4双特异性抗体）在晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学特征和有效性的I/II期临床研究

主要目的：在晚期或转移性实体瘤患者中评估MAX-40279与KN046联合用药的有效性和安全性。

开始日期2022-07-25

申办/合作机构

广州再极医药科技有限公司

CTR20220842